ArticleAIDS and behavior2026
Doxycycline Post-exposure Prophylaxis Awareness and Use Among Transgender Women in San Francisco, 2023-2024: Assessment One Year After Release of Health Department Guidance.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Traveling with HIV.Tropical diseases, travel medicine and vaccines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The San Francisco health department released guidelines on doxycycline post-exposure prophylaxis (doxy-PEP) for sexually transmitted infection (STI) prevention in October 2022. Guidelines recommended doxy-PEP for transgender women (hereafter trans women) and men who have sex with men with a history of bacterial STI and condomless anal or oral sex in the last year. We assessed doxy-PEP awareness and use among trans women in San Francisco using National HIV Behavioral Surveillance (NHBS) data from July 2023-May 2024, spanning 9-19 months after guideline release. In-person interviews recorded demographics, behaviors, HIV serostatus, STI history, and doxy-PEP awareness, discussion with a provider, and use in the last year. Among 339 trans women surveyed, 37% were aware of doxy-PEP. In the last year, 20% discussed doxy-PEP with a provider and 11% used doxy-PEP. Among trans women not living with HIV, awareness was correlated with age under 50 years (AOR 3.86, CI 1.92-7.74), engaging in sex work (AOR 1.85, 95% CI 1.02-3.38), and testing positive for a bacterial STI (AOR 2.92, 95% CI 1.35-6.33). Among those living with HIV, awareness of doxy-PEP was correlated with testing positive for an STI (OR 3.05, 95% CI 1.22-7.64). Despite efficacy demonstrated for trans women in clinical trials and health department guidelines prioritizing doxy-PEP for trans women, awareness of this effective STI prevention method was low. These findings mirror the experience with HIV PrEP roll-out for trans women. Targeted interventions and differentiated delivery models are needed to improve access, engagement, and uptake in this population.
Indexed as
Identifiers
41075058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.